Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.

about

P2860

Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.

Item

http://www.wikidata.org/entity/Q38970911

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.

@en

type

Item

label

Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.

@en

prefLabel

Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.

@en

P1433

Q38970911-F6DE48D0-0A83-437A-80B3-848F970B22C2

P1476

Q38970911-1E28E3B5-04E9-4FC5-B2BC-8C19BD0CED34

P2093

Q38970911-0542336A-E2DE-4B44-9B8A-A28AB24ED911

Q38970911-0E493C61-50CA-47E9-8EF1-4F56DDA49353

Q38970911-2B31D927-8FC9-4034-A013-57E25E78954B

Q38970911-35AC5FCA-FA4C-4CE6-9E6E-DFC3CEAE27FB

Q38970911-429A1E0E-CA5A-45C0-980F-06BAC52B55BF

Q38970911-68590380-84A1-4FEC-83C4-FD39A2931790

Q38970911-F18CE752-620F-4992-A57E-A375C098CBE0

P2860

Q38970911-059C7822-1F98-4CFE-BC31-592D957D20A2

Q38970911-098CB80C-F745-4E87-8239-F3E7B281D61D

Q38970911-0A604A66-D9D7-470D-A3F4-E45DF36D8A09

Q38970911-0FB0F34E-5DA1-483F-B192-A3CCCA495E71

Q38970911-17895D10-EDDB-4B9A-82EB-4D3DAF9150F4

Q38970911-2054BE8E-81E1-4016-8FE1-61D1EF2BB538

Q38970911-21239C53-839B-4022-97D6-59C3C8F0D890

Q38970911-22B7E6BC-5D63-448C-AA4A-20E9BB2BF969

Q38970911-2CACF8D5-2215-408A-B067-01B61CC6FDFA

Q38970911-3092D0A9-203D-4F6C-B2B3-F10BD77E2AC7

P2888

Q38970911-E6676A78-DF76-4AF9-829A-C2FA627D008B

P304

Q38970911-92586065-B3B6-4A2D-93EC-A0EB43C1ACC1

P31

Q38970911-57564B7E-1047-40D5-AC2F-9E8A60AE5D1F

P356

Q38970911-C2D4D070-8F5B-498C-B2BD-EFEFE8D84EAA

P407

Q38970911-8C0A7A3B-0F9D-4097-A804-1D86569E5836

P433

Q38970911-3090A5AA-0C00-423A-86B3-C367B04DCD40

P4510

Q38970911-0317EE9B-207A-4F8E-AB88-F9CC24161458

Q38970911-5CE6801B-144D-4F9C-A36E-1028D48F63C3

Q38970911-62D7BF06-650C-4505-93AF-B30117609F71

Q38970911-8AA629CD-F637-499D-9730-7BDB8442A97D

P478

Q38970911-E76B0CB1-DE9A-4677-BFED-82F72BDC4B69

P577

Q38970911-1B0304ED-9ACA-4A48-BAF5-C389ADE9057C

P698

Q38970911-3E32871A-B105-446D-A07F-8E4176AF8DBB

P921

Q38970911-141BA3AE-4324-4FC2-890D-00F406764EF8

P356

S00423-014-1235-1

P1433

Langenbeck's Archives of Surgery

P1476

Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.

@en

P2093

Anna Dupree

http://www.w3.org/2001/XMLSchema#string

Astrid Drenckhan

http://www.w3.org/2001/XMLSchema#string

Jakob R Izbicki

http://www.w3.org/2001/XMLSchema#string

Oliver Mann

http://www.w3.org/2001/XMLSchema#string

Stephanie J Gros

http://www.w3.org/2001/XMLSchema#string

Thorsten Dohrmann

http://www.w3.org/2001/XMLSchema#string

Tobias Grob

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.

Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Oesophageal carcinoma.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

P2888

s00423-014-1235-1

P304

879-888

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00423-014-1235-1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P4510

P478

399

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25070024

http://www.w3.org/2001/XMLSchema#string

P921

cell line